1383439-80-2

Upstream product

• 196810-28-3 <2-(4-fluorophenyl)-5-methyloxazol-4-yl>acetic acid methyl ester 
• 196810-30-7 2-[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]ethanol 
• 105983-77-5 methyl 4-bromo-3-oxopentanoate 
• 824-75-9 p-fluorobenzamide 
• 30414-53-0 methyl propanoyl acetate 
• 1071-73-4 5-Hydroxy-2-pentanone 
• 477541-31-4 2-[2-(4-fluorophenyl)-5-methyloxazol-4-yl]ethyl methanesulfonate 
• 847346-69-4 C₁₂H₁₆O₃ 
• 1352086-02-2 2-[2-(4-fluorophenyl)-5-methyloxazol-4-yl]ethyl benzoate 
• 1352086-00-0 3-(4-fluorobenzamido)-4-carbonylpentyl benzoate 
• 1352085-98-3 3-bromo-4-carbonylpentyl benzoate 

Downstream Products

• 1352085-87-0 3-(2-ethyl-4-{2-[2-(4-fluorophenyl)-5-methyloxazol-4-yl]ethoxyl}phenyl)propionic acid 

Relevant academic research and scientific papers

Design and synthesis of 3-(2-ethyl-4-{2-[2-(4-fluorophenyl)- 5-methyloxazol-4-yl]ethoxy}phenyl)propanoic acid: A novel triple-acting PPARα, -γ, and -δ Agonist

The design and synthesis of triple-acting PPARα, -γ, and -δ agonist 3-(2-ethyl-4-{2-[2-(4-fluorophenyl)-5-methyloxazol-4-yl]- ethoxy}phenyl)propanoic acid (1a) is described. The compound possesses a potent triple-acting PPARα, -γ, and -δ agonist profile with an EC50 of 0.029, 0.013, and 0.029 μM, respectively. The synthetic route, involving the synthesis of oxazole rings as the key step, starts from commercially available 3-oxopentanoic acid methyl ester and 3- hydroxyacetophenone to afford the target compound 1 with an overall yield of 32%.